Pharmaceuticals

Vivaglobin Market 2026 growing with immunodeficiency treatment demand

March 27, 2026March 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Vivaglobin Market During 2026–2030?

Past growth can be linked to enhanced diagnosis rates for primary immunodeficiency disorders, greater clinical adoption of SCIg therapies, the expansion of specialty pharmacy networks, the availability of plasma-derived therapeutics, and increasing physician understanding of immune disorders.

Anticipated expansion throughout the projection period is driven by a surge in demand for self-administered immunoglobulin treatments, the proliferation of personalized immunotherapy approaches, greater investment in rare disease treatment pipelines, an expanding elderly demographic experiencing immune disorders, and technological advancements in plasma fractionation.

Prominent patterns over the forecast duration encompass the growing adoption of subcutaneous immunoglobulin therapies, a heightened preference for administering treatments in a home setting, an intensifying focus on long-term immune replacement therapies, the broadening of patient-centric dosing solutions, and an increased emphasis on the safety and tolerability of treatments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20369&type=smp

Which Economic Or Industry Drivers Are Impacting The Vivaglobin Market?

The rising prevalence of primary immunodeficiency diseases (PI) is a significant factor propelling the vivaglobin market’s future growth. These conditions involve a deficient or absent immune system, hindering the body’s defense against infections and increasing vulnerability to illnesses. The escalating occurrence of Primary Immunodeficiency Diseases (PI) can be attributed to improved diagnostic methods, heightened awareness and recognition of these conditions, enhanced genetic testing, and better identification of previously undiagnosed cases. Vivaglobin aids primary immunodeficiency diseases by delivering a consistent supply of antibodies via subcutaneous administration, thereby strengthening the immune system’s capacity to fight infections and lessening the frequency and severity of recurring illnesses in affected individuals. For example, a report from Thermo Fisher, a US-based life science and clinical research company, indicated in August 2023 that approximately 6 million people worldwide are estimated to have a PID. Additionally, around 5,000 individuals in the UK are believed to suffer from PID disorder. Consequently, the increasing prevalence of Primary Immunodeficiency Diseases (PI) is anticipated to stimulate growth in the vivaglobin market. Increased investment in research and development is projected to drive the vivaglobin market’s expansion moving forward. Medical R&D encompasses the systematic exploration of new drugs, treatments, or technologies to advance healthcare, involving clinical trials, laboratory experiments, and regulatory processes to ensure both safety and effectiveness. Enhanced R&D in medicine fosters the discovery of innovative treatments, improves patient outcomes, and addresses evolving health challenges. Specifically, heightened research and development supports vivaglobin by stimulating advancements in immunoglobulin formulations, refining administration techniques, and improving treatment efficacy and accessibility for patients with primary immunodeficiency diseases. For instance, The Office for National Statistics (ONS), a UK-based producer of official statistics, reported in April 2025 that the UK government’s net R&D expenditure grew by 8.2% year-on-year, rising from £16.1 billion in 2022 to £17.4 billion in 2023. Therefore, increasing investment in research and development is fueling the growth of the vivaglobin market.

How Are The Various Segments Of The Vivaglobin Market Categorized?

The vivaglobin market covered in this report is segmented –

1) By Indication: Primary Immune Deficiency (PID), Secondary Immune Deficiency (SID), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies

3) By End User: Adult, Geriatric, Pediatric

Which Major Firms Influence Developments In The Vivaglobin Market?

Major companies operating in the vivaglobin market are CSL Behring GmbH

Read the full vivaglobin market report here:

https://www.thebusinessresearchcompany.com/report/vivaglobin-global-market-report

What Are The Top-Performing Regions Within The Vivaglobin Market?

North America was the largest region in the vivaglobin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the vivaglobin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Vivaglobin Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20369&type=smp

Browse Through More Reports Similar to the Global Vivaglobin Market 2026, By The Business Research Company

Antiglaucoma Drugs Market 2026

https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-market

Bevacizumab Biosimilars Market Report 2026

https://www.thebusinessresearchcompany.com/report/bevacizumab-biosimilars-global-market-report

Isotretinoin Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/isotretinoin-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795